Erratum to Dual actions of a novel bifunctional compound to lower glucose in mice with diet-induced insulin resistance (Am J Physiol Endocrinol Metab, (2015) 309, (E293-E301), 10.1152/ajpendo.00045.2015);Dual actions of a novel bifunctional compound to lower glucose in mice with diet-induced insulin resistance

American Journal of Physiology - Endocrinology and Metabolism

Volumn 309, Issue 3, 2015, Pages E293-E301

  Chen, Katherine ^a   Jih, Alice ^a   Kavaler, Sarah T ^a   Lagakos, William S ^a   Oh, Dayoung ^a   Watkins, Steven M ^b   Kim, Jane J ^a,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b METABOLON INC   (United States)

^c RADY CHILDREN'S HOSPITAL   (United States)

Author keywords

Docosahexaenoic acid; Insulin resistance; Obesity; Salicylate

Indexed keywords

4 IODO 2,5 DIMETHOXYAMPHETAMINE; ACTIN; DOCOSAHEXAENOIC ACID; EXENDIN[9-39]; GLUCAGON LIKE PEPTIDE 1; GLUCOSE; HEMOGLOBIN A1C; HORMONE RECEPTOR BLOCKING AGENT; I KAPPA B ALPHA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INSULIN; INTERLEUKIN 1BETA; MONOCYTE CHEMOTACTIC PROTEIN 1; SALICYLIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; NONSTEROID ANTIINFLAMMATORY AGENT; PRODRUG; SAL-DHA COMPOUND; SALICYLIC ACID DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHRONIC INFLAMMATION; CONTROLLED STUDY; DIET INDUCED OBESITY; DRUG EFFECT; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; HORMONE RELEASE; HUMAN; HUMAN CELL; HYPERGLYCEMIA; INSULIN RESISTANCE; MACROPHAGE; MALE; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; ADVERSE EFFECTS; AGONISTS; ANALYSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL CULTURE; COMPARATIVE STUDY; CYTOLOGY; DRUG EFFECTS; IMMUNOLOGY; LIPID DIET; LIVER; METABOLISM; OBESITY; ORAL DRUG ADMINISTRATION; PATHOLOGY; PATHOPHYSIOLOGY; PREDIABETIC STATE; SIGNAL TRANSDUCTION; TRANSFORMED CELL LINE; TUMOR CELL LINE;

ADMINISTRATION, ORAL; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; BLOOD GLUCOSE; CELL LINE, TRANSFORMED; CELL LINE, TUMOR; CELLS, CULTURED; DIET, HIGH-FAT; DOCOSAHEXAENOIC ACIDS; GLUCAGON-LIKE PEPTIDE 1; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN RESISTANCE; LIVER; MACROPHAGES; MICE, INBRED C57BL; OBESITY; PREDIABETIC STATE; PRODRUGS; SALICYLATES; SIGNAL TRANSDUCTION;

EID: 84938602095     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.zh1-7526-corr.2016     Document Type: Erratum

References (34)

1. Arden KC. FoxO: linking new signaling pathways. Mol Cell 14: 416–418, 2004.
2. Beaven SW, Matveyenko A, Wroblewski K, Chao L, Wilpitz D, Hsu TW, Lentz J, Drew B, Hevener AL, Tontonoz P. Reciprocal regulation of hepatic and adipose lipogenesis by liver X receptors in obesity and insulin resistance. Cell Metab 18: 106–117, 2013.
3. Bhaswant M, Poudyal H, Brown L. Mechanisms of enhanced insulin secretion and sensitivity with n-3 unsaturated fatty acids. J Nutr Biochem 26: 571–584, 2015.
4. Bracey MH, Hanson MA, Masuda KR, Stevens RC, Cravatt BF. Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling. Science 298: 1793–1796, 2002.
5. Cernea S, Raz I. Therapy in the early stage: incretins. Diabetes Care 34, Suppl 2: S264–S271, 2011.
6. Goldfine AB, Fonseca V, Jablonski KA, Pyle L, Staten MA, Shoelson SE. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. Ann Intern Med 152: 346–357, 2010.
7. Hawley SA, Fullerton MD, Ross FA, Schertzer JD, Chevtzoff C, Walker KJ, Peggie MW, Zibrova D, Green KA, Mustard KJ, Kemp BE, Sakamoto K, Steinberg GR, Hardie DG. The ancient drug salicylate directly activates AMP-activated protein kinase. Science 336: 918–922, 2012.
8. He L, Wong CK, Cheung KK, Yau HC, Fu A, Zhao HL, Leung KM, Kong AP, Wong GW, Chan PK, Xu G, Chan JC. Anti-inflammatory effects of exendin-4, a glucagon-like peptide-1 analog, on human peripheral lymphocytes in patients with type 2 diabetes. J Diabet Invest 4: 382–392, 2013.
9. Hellmann J, Tang Y, Kosuri M, Bhatnagar A, Spite M. Resolvin D1 decreases adipose tissue macrophage accumulation and improves insulin sensitivity in obese-diabetic mice. FASEB J 25: 2399–2407, 2011.
10. Hendrich S. (n-3) Fatty acids: clinical trials in people with type 2 diabetes. Adv Nutr 1: 3–7, 2010.
11. Higgs GA, Moncada S, Vane JR. Eicosanoids in inflammation. Ann Clin Res 16: 287–299, 1984.
12. Hirasawa A, Tsumaya K, Awaji T, Katsuma S, Adachi T, Yamada M, Sugimoto Y, Miyazaki S, Tsujimoto G. Free fatty acids regulate gut incretin glucagon-like peptide-1 secretion through GPR120. Nat Med 11: 90–94, 2005.
13. Horvai AE, Xu L, Korzus E, Brard G, Kalafus D, Mullen TM, Rose DW, Rosenfeld MG, Glass CK. Nuclear integration of JAK/STAT and Ras/AP-1 signaling by CBP and p300. Proc Natl Acad Sci USA 94: 1074–1079, 1997.
14. Inokuchi S, Aoyama T, Miura K, Osterreicher CH, Kodama Y, Miyai K, Akira S, Brenner DA, Seki E. Disruption of TAK1 in hepatocytes causes hepatic injury, inflammation, fibrosis, and carcinogenesis. Proc Natl Acad Sci USA 107: 844–849, 2010.
15. Kahles F, Meyer C, Mollmann J, Diebold S, Findeisen HM, Lebherz C, Trautwein C, Koch A, Tacke F, Marx N, Lehrke M. GLP-1 secretion is increased by inflammatory stimuli in an IL-6-dependent manner, leading to hyperinsulinemia and blood glucose lowering. Diabetes 63: 3221–3229, 2014.
16. Kelley DS, Adkins Y, Woodhouse LR, Swislocki A, Mackey BE, Siegel D. Docosahexaenoic acid supplementation improved lipocentric but not glucocentric markers of insulin sensitivity in hypertriglyceridemic men. Metab Syndrome Relat Dis 10: 32–38, 2012.
17. Kelley DS, Siegel D, Vemuri M, Mackey BE. Docosahexaenoic acid supplementation improves fasting and postprandial lipid profiles in hypertriglyceridemic men. Am J Clin Nutr 86: 324–333, 2007.
18. Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI. A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res 23: 1686–1690, 1995.
19. Lu M, Sarruf DA, Talukdar S, Sharma S, Li P, Bandyopadhyay G, Nalbandian S, Fan W, Gayen JR, Mahata SK, Webster NJ, Schwartz MW, Olefsky JM. Brain PPAR-(gamma) promotes obesity and is required for the insulin-sensitizing effect of thiazolidinediones. Nat Med 17: 618–622, 2011.
20. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and betacell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 28: 412–419, 1985.
21. Moller DE. Metabolic disease drug discovery- “hitting the target” is easier said than done. Cell Metab 15: 19–24, 2012.
22. Morishita M, Tanaka T, Shida T, Takayama K. Usefulness of colon targeted DHA and EPA as novel diabetes medications that promote intrinsic GLP-1 secretion. J Control Release 132: 99–104, 2008.
23. Nguyen MT, Favelyukis S, Nguyen AK, Reichart D, Scott PA, Jenn A, Liu-Bryan R, Glass CK, Neels JG, Olefsky JM. A subpopulation of macrophages infiltrates hypertrophic adipose tissue and is activated by free fatty acids via Toll-like receptors 2 and 4 and JNK-dependent pathways. J Biol Chem 282: 35279–35292, 2007.
24. Oh da Y, Walenta E, Akiyama TE, Lagakos WS, Lackey D, Pessentheiner AR, Sasik R, Hah N, Chi TJ, Cox JM, Powels MA, Di Salvo J, Sinz C, Watkins SM, Armando AM, Chung H, Evans RM, Quehenberger O, McNelis J, Bogner-Strauss JG, Olefsky JM. A Gpr120- selective agonist improves insulin resistance and chronic inflammation in obese mice. Nat Med 20: 942–947, 2014.
25. Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, Li P, Lu WJ, Watkins SM, Olefsky JM. GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 142: 687–698, 2010.
26. Olefsky JM, Glass CK. Macrophages, inflammation, and insulin resistance. Annu Rev Physiol 72: 219–246, 2010.
27. Ricote M, Huang J, Fajas L, Li A, Welch J, Najib J, Witztum JL, Auwerx J, Palinski W, Glass CK. Expression of the peroxisome proliferator- activated receptor gamma (PPARgamma) in human atherosclerosis and regulation in macrophages by colony stimulating factors and oxidized low density lipoprotein. Proc Natl Acad Sci USA 95: 7614–7619, 1998.
28. Rossmeisl M, Jilkova ZM, Kuda O, Jelenik T, Medrikova D, Stankova B, Kristinsson B, Haraldsson GG, Svensen H, Stoknes I, Sjovall P, Magnusson Y, Balvers MG, Verhoeckx KC, Tvrzicka E, Bryhn M, Kopecky J. Metabolic effects of n-3 PUFA as phospholipids are superior to triglycerides in mice fed a high-fat diet: possible role of endocannabinoids. PloS One 7: e38834, 2012.
29. Rumore MM, Kim KS. Potential role of salicylates in type 2 diabetes. Ann Pharmacother 44: 1207–1221, 2010.
30. Scheen AJ, Esser N, Paquot N. Antidiabetic agents: Potential antiinflammatory activity beyond glucose control. Diabetes Metab 2015.
31. Serhan CN. Systems approach to inflammation resolution: identification of novel anti-inflammatory and pro-resolving mediators. J Thromb Haemost 7, Suppl 1: 44–48, 2009.
32. Yang L, Inokuchi S, Roh YS, Song J, Loomba R, Park EJ, Seki E. Transforming growth factor-beta signaling in hepatocytes promotes hepatic fibrosis and carcinogenesis in mice with hepatocyte-specific deletion of TAK1. Gastroenterology 144: 1042–1054 e1044, 2013.
33. Yuan M, Konstantopoulos N, Lee J, Hansen L, Li ZW, Karin M, Shoelson SE. Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkbeta. Science 293: 1673–1677, 2001.
34. Zhao L, Chen Y, Tang R, Chen Y, Li Q, Gong J, Huang A, Varghese Z, Moorhead JF, Ruan XZ. Inflammatory stress exacerbates hepatic cholesterol accumulation via increasing cholesterol uptake and de novo synthesis. J Gastroenterol Hepatol 26: 875–883, 2011.